Clinical Trial: NCT04436107
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | BeiGene |
| Information Provided By: | BeiGene |
| Last Update Posted: | 2025-05-23 |
Study Overview
Brief Summary
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL
Official Title
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study of Bruton Tyrosine Kinase (BTK) Inhibitor, Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Intervention / Treatment
- Drug: Zanubrutinib
- Drug: Lenalidomide
Other Study ID Numbers
- BGB-3111-110
Start Date (Actual)
2020-09-11
Primary Completion Date (Actual)
2024-03-28
Study Completion Date (Actual)
2024-03-28
Enrollment (Actual)
66
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | BeiGene |
| Information Provided By: | BeiGene |
| Last Update Posted: | 2025-05-23 |
Study Overview
Brief Summary
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL
Official Title
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study of Bruton Tyrosine Kinase (BTK) Inhibitor, Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Intervention / Treatment
- Drug: Zanubrutinib
- Drug: Lenalidomide
Other Study ID Numbers
- BGB-3111-110
Start Date (Actual)
2020-09-11
Primary Completion Date (Actual)
2024-03-28
Study Completion Date (Actual)
2024-03-28
Enrollment (Actual)
66
Study Type
Interventional
Phase
Phase 1